These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 18057928)

  • 1. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
    Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
    Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
    Cabrera SE; Santos D; Valverde MP; Domínguez-Gil A; González F; Luna G; García MJ
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
    Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Kenu E; Court MH
    AIDS; 2009 Oct; 23(16):2101-6. PubMed ID: 19779319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
    Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
    Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
    Jamshidi Y; Moreton M; McKeown DA; Andrews S; Nithiyananthan T; Tinworth L; Holt DW; Sadiq ST
    J Antimicrob Chemother; 2010 Dec; 65(12):2614-9. PubMed ID: 20952418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
    Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
    PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
    Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
    J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
    Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
    J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.